BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Feature

Scaling Personalised Therapies Across APAC Starts With Supply Chain Readiness

As cell and gene therapies advance across Asia-Pacific, supply chains must connect complex manufacturing processes with individual patients’ treatmen...

November 12, 2026 | Expert Insight

Purity Is Not Content: What Research Buyers Check on a Peptide Certificate of Analysis

This analysis comes from the distributor's side of that transaction. BulkGLP is a US supplier of research peptides that publishes its lot reports online. B...

November 11, 2026 | Analysis

The 10 APAC Universities and Institutes Turning Research Into Licensed Drug Assets

Every November, the same ritual plays out in a European convention hall. University technology-transfer offices arrive with slides counting patents filed, ...

November 11, 2026 | Analysis

APAC Antibody-Drug Conjugates Past Phase 2, and Who Owns Them Now

Seventeen of them have already been licensed outside their home market, and the companies that will sell most of them in the US and Europe are Merck, Astra...

November 05, 2026 | Analysis

China's 2026 Reimbursement Lists: 10 Drugs That Will Show Where Beijing Is Paying, and the Commercial List's Second Year

Where things stand. As of 2 November 2026, the National Healthcare Security Administration (NHSA) has not published the 2026 National Reimbursement Drug Li...

November 03, 2026 | Regulatory

APAC-Originated Obesity Drugs in the Clinic, Beyond Semaglutide

Obesity was the most searched therapeutic area of 2026, and for most readers the story still has two names in it. Semaglutide and tirzepatide set the bench...

November 02, 2026 | Analysis

Japan's FY2027 Off-Year Drug Price Revision: 8 Numbers That Decide Who Pays

Japan's off-year drug price revision stopped being a question of whether some time ago. When the health and finance ministers closed the FY2026 budget roun...

October 29, 2026 | Analysis

17 APAC-Made Biosimilars Approved in the US or EU in 2026

Seventeen times in 2026, the US Food and Drug Administration or the European Commission cleared a biosimilar that was developed or made in Asia-Pacific. Ni...

October 28, 2026 | Analysis

Orphan Drug Incentives in 9 APAC Markets, Compared

Every January, regulatory affairs teams across Asia-Pacific rebuild the same spreadsheet. Which markets will designate this asset as an orphan? Which will ...

October 27, 2026 | Analysis

The Batch Record Bottleneck in Life Sciences

Walk into the finished goods area of almost any medical device plant at the end of a quarter and you will find the same quiet scene. Pallets of product sit...

October 22, 2026 | Analysis

What Eight APAC Regulators Have Actually Published on AI in Drug Development

Ask a regulatory affairs lead in Tokyo, Seoul or Singapore what the rules are for using a machine learning model in a drug submission, and the honest answe...

October 22, 2026 | Analysis

How Long It Takes to Start a Clinical Trial in 8 APAC Markets, Timed

If you are building a 2027 trial budget this month, you are probably working from a spreadsheet with one row per country and a column headed "start-up". Mo...

October 19, 2026 | News

Mitochondrial-Derived Peptides: What Research Has Shown So Far

Scientists have described eight MDPs: humanin, MOTS-c and six small humanin-like peptides (SHLP1 to SHLP6). Research has focused on different aspects of th...

October 12, 2026 | News

From Academic Discovery to Biopharma Impact: Strengthening Southeast Asia’s Translation Pathway

Universities and public research institutes across the region are advancing research in cancer treatment, cell therapy, biologics and other emerging fields...

October 07, 2026 | Opinion | By Hajjerah TMK Hassan, Director, Discovery and Channels - ASEAN |Cytiva

Stay Connected